5-Methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients

American Journal of Nephrology

Volumn 28, Issue 6, 2008, Pages 941-948

  Cianciolo, Giuseppe ^a   La Manna, Gaetano ^a,b   Colì, Luigi ^a   Donati, Gabriele ^a   D'Addio, Francesca ^a,b   Persici, Elisa ^a,b   Comai, Giorgia ^a,b   Wratten, Marylou ^c   Dormi, Ada ^b   Mantovani, Vilma ^a   Grossi, Gabriele ^a   Stefoni, Sergio ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Cyberonics Inc   (Italy)

Author keywords

5 Methyltetrahydrofolate; C reactive protein; ESRD patients; ESRD, survival; Homocysteine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; EPARGRISEOVIT; FOLIC ACID; FOLINA; HOMOCYSTEINE; LIPOPROTEIN A; PREFOLIC; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DNA POLYMORPHISM; DRUG MEGADOSE; FEMALE; GENETIC POLYMORPHISM; GROUPS BY AGE; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

AGED; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK; RISK FACTORS; TETRAHYDROFOLATES; VITAMIN B 12; VITAMIN B 6;

EID: 53549083760     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000142363     Document Type: Article

References (35)

1. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS: Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004;65:2380-2389.
2. Bayés B, Pastor MC, Bonal J, Romero R: 'New' cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment. Kidney Int Suppl 2005:S39-S43.
3. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274:1526-1533.
4. Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C: Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004;17:405-410.
5. Mallamaci F, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Candela V, Scudo P, Spoto B, Testa A, Tripepi G, Tech S, Zoccali C: Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis 2005;45:702-707.
6. Perna AF, De Santo NG, Ingrosso D: Adverse effects of hyperhomocysteinemia and their management by folic acid. Miner Electrolyte Metab 1997;23:174-178.
7. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD: A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004;15:442-453.
8. Nair AP, Nemirovsky D, Kim M, Geer EB, Farkouh ME, Winston J, Halperin JL, Robbins MJ: Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med 2005;72:365-373.
9. Bayes B, Pastor MC, Bonal J, Junca J, Hernandez JM, Riutort N, Foraster A, Romero R: Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003;18:106-112.
10. Bowden RG, Wyatt FB, Wilson R, Wilborn C, Gentile M: Homocysteine and vascular access thrombosis in a cohort of end-stage renal disease patients. Ren Fail 2004;26:709-714.
11. Chen TC, Wang IK, Lee CH, Chang HW, Chiou TT, Lee CT, Fang JT, Wu MS, Hsu KT, Yang CC, Wang PH, Chiang FR: Hyperhomocysteinaemia and vascular access thrombosis among chronic hemodialysis patients in Taiwan: a retrospective study. Int J Clin Pract 2006;60:1596-1599.
12. Chuang FR, Fang JT, Chen JB, Lin CL, Chen HY, Lee CN, Wang PH, Lee CH: Hyperhomocysteinemia and the prevalence of symptomatic atherosclerotic vascular disease in Taiwanese chronic hemodialysis patients: a retrospective study. Ren Fail 2003;25:765-774.
13. Dennis VW, Robinson K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl 1996;57:S11-S17.
14. Suliman ME, Stenvinkel P, Heimburger O, Barany P, Lindholm B, Bergstrom J: Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 2002;40:480-488.
15. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R: Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-2416.
16. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, NORVIT Trial Investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
17. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr, Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577.
18. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drüeke T, Massy ZA: Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999;56:2292-2296.
19. Bostom AG, Shemin D, Bagley P, Massy ZA, Zanabli A, Christopher K, Spiegel P, Jacques PF, Dworkin L, Selhub J: Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000;101:2829-2832.
20. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP: Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-426.
21. Van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Jakobs C, Donker AJ, Stehouwer CD: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998;13: 106-112.
22. Manns B, Hyndman E, Burgess E, Parsons H, Schaefer J, Snyder F, Scott-Douglas N: Oral vitamin B 12 and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia. Kidney Int 2001;59:1103-1109.
23. Araki A, Sako Y: Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52.
24. Sassi S, Grossi G, Bozza D, Mirighi R: Plasma pyridoxal-5′- phosphate determination by HPLC after pre-column derivatization. 21st International Symposium on High-Performance Liquid Phase Separations and Related Techniques, Birmingham/UK, 1997.
25. Schneider JA, Rees DC, Liu YT, Clegg JB: Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998;62:1258-1260.
26. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G: Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999;96:12810-12815.
27. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, Enzenberger B, Janata O, Winkerlmayer WC, Paul G, Auinger M, Barnas U, Hörl WH: Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000;11:1106-1116.
28. Kimura H, Gejyo F, Suzuki S, Miyazaki R: The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. J Am Soc Nephrol 2000;11:885-893.
29. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LG, Howard VJ, Sides EG, Wang CH, Stampfer M: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
30. Willems FF, Boers GH, Blom HJ, Aengevaeren WR, Verheugt FW: Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol 2004;141:825-830.
31. Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG: Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol 2002;282:H2167-H2172.
32. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, Rabelink TJ: Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000;86:1129-1134.
33. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, Channon KM: 5- Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006;114:1193-1201.
34. Baragetti I, Raselli S, Stucchi A, Terraneo V, Furiani S, Buzzi L, Garlaschelli K, Alberghini E, Catapano AL, Buccianti G: Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration. Nephrol Dial Transplant 2007;22:3292-3297.
35. Buccianti G, Raselli S, Baragetti I, Bamonti F, Corghi E, Novembrino C, Patrosso C, Maggi FM, Catapano AL: 5-Methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002;17:857-864.